Precigen, Inc.

Precigen Inc. is a biotechnology company that focuses on the development of innovative gene therapies. Its primary mission is to harness the power of synthetic biology and gene therapy technologies to bring novel treatments to patients with cancer and other challenging diseases. Precigen Inc. leverages its proprietary UltraCAR-T platform, a cutting-edge approach to engineering T-cells, which are designed to enhance the body’s immune response against cancer cells. The company also explores other therapeutic areas, including autoimmune disorders and infectious diseases, with its diverse portfolio of advanced technologies. By pushing the boundaries of genetic science, Precigen Inc. plays a crucial role in the biopharmaceutical sector, contributing to the advancement of personalized medicine and precision therapies that aim to address unmet medical needs. Headquartered in Germantown, Maryland, the company continues to lead transformative research efforts, positioning itself as a significant player in the dynamic landscape of modern healthcare solutions.